Mercer Global Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q3 | $17.4M | Buy |
33,313
+2,608
| +8% | +$1.34M | 0.02% | 417 |
|
|
2026
Q2 | $15.3M | Buy |
30,705
+7,943
| +35% | +$3.52M | 0.02% | 442 |
|
|
2026
Q1 | $10.2M | Sell |
22,762
-1,060
| -4% | -$494K | 0.02% | 496 |
|
|
2025
Q4 | $8.99M | Buy |
23,822
+5,038
| +27% | +$2.17M | 0.01% | 521 |
|
|
2025
Q3 | $7.36M | Buy |
18,784
+261
| +1% | +$109K | 0.01% | 546 |
|
|
2025
Q2 | $8.25M | Buy |
18,523
+3,462
| +23% | +$1.6M | 0.02% | 437 |
|
|
2025
Q1 | $7.3M | Buy |
15,061
+1,053
| +8% | +$491K | 0.02% | 449 |
|
|
2024
Q4 | $5.64M | Sell |
14,008
-1,543
| -10% | -$715K | 0.01% | 512 |
|
|
2024
Q3 | $7.3M | Sell |
15,551
-952
| -6% | -$457K | 0.02% | 399 |
|
|
2024
Q2 | $7.7M | Buy |
16,503
+3,106
| +23% | +$1.35M | 0.02% | 358 |
|
|
2024
Q1 | $5.6M | Sell |
13,397
-1,119
| -8% | -$473K | 0.02% | 433 |
|
|
2023
Q4 | $5.91M | Buy |
14,516
+2,789
| +24% | +$1.03M | 0.02% | 421 |
|
|
2023
Q3 | $4.08M | Buy |
11,727
+713
| +6% | +$249K | 0.02% | 486 |
|
|
2023
Q2 | $3.88M | Buy |
11,014
+899
| +9% | +$303K | 0.02% | 519 |
|
|
2023
Q1 | $3.19M | Buy |
10,115
+1,821
| +22% | +$546K | 0.01% | 553 |
|
|
2022
Q4 | $2.4M | Buy |
8,294
+170
| +2% | +$51.8K | 0.01% | 648 |
|
|
2022
Q3 | $2.35M | Sell |
8,124
-835
| -9% | -$240K | 0.01% | 590 |
|
|
2022
Q2 | $2.52M | Sell |
8,959
-1,127
| -11% | -$302K | 0.02% | 552 |
|
|
2022
Q1 | $2.63M | Buy |
10,086
+613
| +6% | +$145K | 0.02% | 566 |
|
|
2021
Q4 | $2.08M | Buy |
9,473
+2,251
| +31% | +$438K | 0.01% | 608 |
|
|
2021
Q3 | $1.31M | Buy |
7,222
+814
| +13% | +$159K | 0.01% | 762 |
|
|
2021
Q2 | $1.29M | Sell |
6,408
-11,397
| -64% | -$2.38M | 0.01% | 736 |
|
|
2021
Q1 | $3.83M | Buy |
17,805
+12,652
| +246% | +$2.78M | 0.03% | 354 |
|
|
2020
Q4 | $1.22M | Sell |
5,153
-1,651
| -24% | -$379K | 0.02% | 551 |
|
|
2020
Q3 | $1.85M | Buy |
6,804
+687
| +11% | +$190K | 0.03% | 405 |
|
|
2020
Q2 | $1.78M | Buy |
6,117
+4,667
| +322% | +$1.27M | 0.03% | 352 |
|
|
2020
Q1 | $345K | Sell |
1,450
-47
| -3% | -$10.8K | 0.01% | 766 |
|
|
2019
Q4 | $328K | Sell |
1,497
-10
| -0.7% | -$2.02K | 0.01% | 882 |
|
|
2019
Q3 | $255K | Buy |
1,507
+49
| +3% | +$8.67K | 0.01% | 946 |
|
|
2019
Q2 | $267K | Buy |
1,458
+29
| +2% | +$5.07K | 0.01% | 923 |
|
|
2019
Q1 | $263K | Buy |
+1,429
| New | +$264K | 0.01% | 868 |
|
Other funds holding VRTX
Mercer Global Advisors's VRTX Position: Q3 2026 in Review
Mercer Global Advisors increased its Vertex Pharmaceuticals (VRTX) stake by 8.5% in Q3 2026, buying an estimated $1.34M and bringing the position to 33,313 shares worth $17.4M. The position accounts for 0.02% of the portfolio, ranked #417.
Mercer Global Advisors first reported a position in VRTX in Q1 2019 and has held it in 31 quarters since. 1,798 funds tracked by Wall St. Rank hold VRTX as of Q3 2026.
- Mercer Global Advisors held 33,313 shares of Vertex Pharmaceuticals worth $17.4M as of Q3 2026.
- Mercer Global Advisors bought 2,608 Vertex Pharmaceuticals shares in Q3 2026, an estimated $1.34M.
- Vertex Pharmaceuticals made up 0.02% of Mercer Global Advisors's portfolio in Q3 2026, its #417 holding.
- Mercer Global Advisors first reported a position in Vertex Pharmaceuticals in Q1 2019 and has held it in 31 quarters since.
- 1,798 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2026.
Based on Mercer Global Advisors's 13F filing for Q3 2026, filed 16 Nov 2026.